FDA rejected ITM Isotope Technologies Munich SE’s radiopharmaceutical therapy ITM-11 due to manufacturing issues, cutting off a potential competitor to Novartis’ radiopharma franchise. Separately, STAT+ highlighted how the promise of radiopharmaceutical targeting is colliding with emerging safety concerns, including unintended radiation exposure to organs such as kidneys and liver.